Member Info for Scinv_temp

*subcutaneous cpis (autocorrect)

*actually I meant the first figure, 0m from IPOs in 2023 and 2024, lots from other sources

Check the figures at the end of this article (do read the report as well)

https://biotechfinance.org/

Sure there is a general sort of stagnation, but it mostly concerns IPOs, innovative companies DON'T WANT to be listed, not because the markets in general are crap, it is the UK stockmarket that is crap and especially AIM that is where typically IPO's happen.

To give a further insight, manage the business of a small private UK biotech, we started in 2022 (with myself full time since h2 2023) and our signed contracts value is over £150M already. The same founder had another business before which they sold to a large US company (listed) back in 2019 for, well, a lot. Them, and others I know of, would NEVER, EVER even consider going public and the main reason apart from the existing regulatory overhead is that their valuation would depend on the projected image of the company more so than their actual innovative approach and hard data. So most don't even consider listing on AIM and they never will so long as valuations are so heavily dependent on blarney. That's what needs to be fixed in AIM.

So -> is for management ...

Sadly the issue is much deeper and it is that of true innovation...

PS the only thing the UK markets need in my opinion so for management to be held accountable in the same way it does in the US for what they promise vs what they deliver. This not only will protect individual investors but will also help to reward trully innovating companies vs blarney pumping ones

Ray, Arecors main business is rapid acting insulin. The global market value is about $7.5B (£6B), dominated by Novo Nordisk, Eli Lilly and Sanofi who not only have their own pipeline for next generation products but these extend to cell/device combination where beta cell in a device can produce insulin as needed perpetually. So Arecor is a small (albeit, as far as I can see by briefly looking, a well run one) formulation company whose most advanced product is a plain old insulin pump competing against giants that are one step ahead.

That is the reason for their valuation, not the "dismal UK markets"

Oooooor, you are a delusional fool.

You think hook is like a spac in this deal?

🤣🤣🤣🤣🤣🤣🤣🤣

You don't own the combined entity you fool.

But you know what, most of you deserve what Cathal does to you. Polb had twice the market cap of hook and they gave you 55% of the combined entity pre-dilution (40% after dilution), which gets to keep the £13M ($17M) polb has in cash AND original hook holder get most of the upside that could come from their gilead deal. So polb holders collectively owned 100% of £35M (market cap of polb) and If you take into account the dilution from the $30M they want to raise, you will now own 40% of a company that will barely have a market cap of $40M (£30M), if that.

But don't let me ruin the impression that you are winning🤣🤣🤣🤣

PS As I said many times before, POLB001 is absolute garbage

🤣🤣🤣🤣🤣🤣

Dude they just bought you for 11.5M.

Mcap $24M, looking to raise $30M + another 55% dilution of hook holders because of the merger. What do you think?

What you need to understand as well is that the company has no IP of great value and also not the funds to at least get to some limited protection (5yrs max but probably closer to 3) as a reward for their clinical development efforts. Unfortunately it doesn't work, despite what management says. This isn't the first, or the second, or the third, or the fourth trial it failed. Maybe there was chance that at least for a very niche population it could work reasonably well, but the kind of trial they propose isn't that, in fact it is more or less the same type of population they've always tested it in for the past 2 decades, so whatever patents they have remaining, they just secure freedom to operate rather than excluding others, despite what RM said.

So yeah, AT BEST, they value POLB assets (besides cash) at around £11M. Only fools can be happy about that.

Sol, all they did is "buy" the cash which they need. Remember that according to the rns, current polb shareholders get very little of the upside with gilead which is the only play they have going for them.

In the end they give away very little to get the cash, since they do plan to dilute anyway and independently of the dilution associated with the merger. If you exclude POLB cash, they are giving about £11M worth of shares (if that since I don't agree with the sentiment that hook will rise as a result of this merger. POLB management on the other hand have the opportunity to disengage from a company that goes nowhere without actually folding.

The product is useless otherwise the hook deal would not have been so crappy for you.

According to last report, POLB has £13M in cash and equivalents incl receivables. The takeover values POLB at £24.5M minus the cash and you will find that you got bought for £11.5M and celebrating🤣🤣🤣🤣

What really matters is the pps of HOOK when you get their shares so if you think HOOK is going to do well, you are still better of selling now and buy their shares directly, though I would not touch either.

Ooooor, you are all fools. Let's see what happens.

Not a Panacea is correct obviously :)